MT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
Stocktwits40d agoneutral
IOVA Stock Hits Over 2-Year Highs - Why Iovance Raised Its FY2026 Revenue OutlookInvesting.com40d agobullish
Iovance shares jump in premarket as raised outlook clears consensus views